Journal of Literature Pharmacy Sciences

Epilepsi Tedavisinde Klinik Kanıta Dayalı Farmakokinetik Bitkisel Ürün/Metabolit-İlaç Etkileşimi: Geleneksel Derleme
Clinical Evidence-Based Pharmacokinetic Herbal Product/ Metabolite-Drug Interaction in the Treatment of Epilepsy: Traditional Review
Tuğba SUBAŞa, İçim GÖKKAYAa, Ufuk ÖZGENa, Gülin RENDAa, Sevim ŞAHİNb
aKaradeniz Teknik Üniversitesi Eczacılık Fakültesi, Farmakognozi ABD, Trabzon, Türkiye
bKaradeniz Teknik Üniversitesi Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları ABD, Trabzon, Türkiye
J Lit Pharm Sci. 2022;11(1):1-14
doi: 10.5336/pharmsci.2021-84642
Article Language: TR
Full Text
ÖZET
 Dünya çapında bitkisel ürün kullanımı giderek yaygınlaşmaktadır. Epilepsi hastaları, tıbbi tedavilerini tamamlamak, epilepsi yönetimini desteklemek ve nöbet sıklığını azaltmak gibi çeşitli amaçlarla bu ürünleri kullanmaya yönelmektedir. Bitkisel ürünlerin konvansiyonel ilaçlarla eş zamanlı kullanılması, bitki-ilaç etkileşimlerine yol açabilir. Bu derlemede, antiepileptik ilaçlar ile bitkisel ürünler ve bitkilerden elde edilen sekonder metabolitlerin farmakokinetik etkileşimi, 1995 ve 2016 yılları arasında gerçekleştirilen 33 klinik çalışmadan hareketle çalışmanın tipi, katılımcıların sayısı ve niteliği, bitkisel ürün ve bitkisel droglardan elde edilen sekonder metabolitler ile antiepileptik ilaçların dozu, kullanım süresi ve bitki-ilaç etkileşimine dair bulgular ele alınarak değerlendirilmiştir. Yapılan araştırmada, antiepileptik ilaçlarla klinik olarak anlamlı farmakokinetik etkileşim gösteren bitkilerin Citrus paradisi Macfad., Echinacea purpurea (L.) Moench, Ginkgo biloba L., Hydrastis canadensis L. ve Hypericum perforatum L.; sekonder metabolitlerin ise diosmin, piperin ve resveratrol olduğu görülmüştür. Çalışmanın devamında, bu bitkilerin ve sekonder metabolitlerin antiepileptik ilaçlarla olası farmakokinetik etkileşim mekanizmaları değerlendirilmiştir. Bitkisel ürünler ve sekonder metabolitler, pregnan X reseptörü aktivasyonu yoluyla sitokrom P450 enzim modülasyonu ve ilaç taşınmasında rol oynayan P-glikoprotein gibi ilaç taşıyıcı proteinleri etkilemek suretiyle antiepileptik ilaçlarla etkileşmektedir. Epilepsi tanılı bireylerde, klinikte terapötik düzeyleri takip edilen antiepileptik ilaçların kan konsantrasyon düzeylerinin subterapötik veya supraterapötik düzeylerde bulunması, durumun bitkisel ürün kullanımıyla ilişkili olduğunu göstermiştir.

Anahtar Kelimeler: Bitkisel ürün; farmakokinetik etkileşim; pregnan X reseptör; P-glikoprotein
ABSTRACT
 The use of herbal products is increasing worldwide. Epilepsy patients tend to use these products for various purposes such as complementing their medical treatments, supporting epilepsy management, and reducing the frequency of seizures. Simultaneous use of herbal products with conventional drugs may lead to herb-drug interactions. In this review, the pharmacokinetic interaction of antiepileptic drugs with herbal products and secondary metabolites has been evaluated in consideration of the type of the study, the number and the nature of the participants, the dose of herbal products, secondary metabolites from herbs, and antiepileptic drugs, the duration of use, the results of herb-drug interactions, based on 33 clinical studies conducted between 1995-2016. In the study, it has been observed that plants showing clinically significant pharmacokinetic interactions with antiepileptic drugs are Citrus paradisi Macfad., Echinacea purpurea (L.) Moench, Ginkgo biloba L., Hydrastis canadensis L., and Hypericum perforatum L. and the secondary metabolites are diosmin, piperine, and resveratrol. Subsequently, the possible pharmacokinetic interaction mechanisms of these plants/secondary metabolites with antiepileptic drugs were evaluated. Herbal products/secondary metabolites interact with antiepileptic drugs by affecting drug carrier proteins such as Pglycoprotein involved in cytochrome P450 enzyme modulation and drug transport through pregnane X receptor activation. The presence of subtherapeutic/supratherapeutic levels of antiepileptic drugs whose therapeutic levels are monitored clinically in individuals with epilepsy has shown that it is associated with the use of herbal products.

Keywords: Herbal product; pharmacokinetic interaction; pregnane X receptor; P-glycoprotein
REFERENCES:
  1. World Health Organization [İnternet]. © 2021 WHO [Erişim tarihi: 14 Mayıs 2021]. Epilepsy. Erişim linki: [Link] 
  2. Stafstrom CE, Carmant L. Seizures and epilepsy: an overview for neuroscientists. Cold Spring Harb Perspect Med. 2015;5(6):a022426. [Crossref]  [PubMed]  [PMC] 
  3. Johnson EL. Seizures and epilepsy. Med Clin North Am. 2019;103(2):309-24. [Crossref]  [PubMed] 
  4. Altındağ E, Erdoğan FF, Tezer İ, Özkara Ç. Çocuk ve erişkin Status epileptikuslu hastaya yaklaşım ve erken dönem tedavisi [Management and early treatment of status epilepticus in adults and children]. Turk J Neurol. 2017;23:155-61. [Crossref] 
  5. Trinka E, Kälviäinen R. 25 years of advances in the definition, classification and treatment of status epilepticus. Seizure. 2017;44:65-73. [Crossref]  [PubMed] 
  6. Epilepsi Çalışma Grubu Tanı ve Tedavi Rehberi 2015. Türk Nöroloji Derneği. 2015. Erişim tarihi: 10 Mayıs 2021. Erişim adresi: [Link] 
  7. Akpınar ÇK, Cengiz N. Status epileptikus'un güncel tanı, tedavi ve etiyolojisi [Current diagnosis, treatment and etiology of status epilepticus]. Epilepsi. 2014;20(1):1-10. [Link] 
  8. İstanbulluoğlu S, Çeliker A. İlaç-bitkisel ürün etkileşimlerinin önlenmesinde eczacının rolü [The role of pharmacist in prevention of drug-herbal product interactions]. FABAD J Pharm Sci. 2018;43(3):291-305. [Link] 
  9. World Health Organisation [İnternet]. WHO © 2018 [Erişim tarihi: 3 Mart 2022]. WHO Expert Committee on Specifications for Pharmaceutical Preparations, Fifty-second report Erişim linki: [Link] 
  10. Resmî Gazete (06.10.2010, Sayı: 27721) sayılı Geleneksel Bitkisel Tıbbi Ürünler Yönetmeliği; 2010. Erişim tarihi: 20 Nisan 2021. Erişim adresi: [Link] 
  11. Chen XW, Sneed KB, Pan SY, Cao C, Kanwar JR, Chew H, et al. Herb-drug interactions and mechanistic and clinical considerations. Curr Drug Metab. 2012;13(5):640-51. [Crossref]  [PubMed] 
  12. Bosak M, Słowik A. Use of complementary and alternative medicine among adults with epilepsy in a university epilepsy clinic in Poland. Epilepsy Behav. 2019;98(Pt A):40-4. [Crossref]  [PubMed] 
  13. Işler A, Turan FD, Gözüm S, Oncel S. Complementary and alternative approaches used by parents of children with epilepsy on epilepsy management. Epilepsy Behav. 2014;32:156-61. [Crossref]  [PubMed] 
  14. Zhou S, Chan E, Pan SQ, Huang M, Lee EJ. Pharmacokinetic interactions of drugs with St John's wort. J Psychopharmacol. 2004;18(2):262-76. [Crossref]  [PubMed] 
  15. Wongnawa M, Soontaro P, Riditid W, Wongpoowarak P, Ruengkittisakul S. The effects of Andrographis paniculata (Burm.f.) Nees on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Songklanakarin J Sci Technol. 2012;34(5):533-9. [Link] 
  16. Gurley B, Hubbard MA, Williams DK, Thaden J, Tong Y, Gentry WB, et al. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J Clin Pharmacol. 2006;46(2):201-13. [Crossref]  [PubMed]  [PMC] 
  17. Andersen V, Pedersen N, Larsen NE, Sonne J, Larsen S. Intestinal first pass metabolism of midazolam in liver cirrhosis --effect of grapefruit juice. Br J Clin Pharmacol. 2002;54(2):120-4. [Crossref]  [PubMed]  [PMC] 
  18. Garg SK, Kumar N, Bhargava VK, Prabhakar SK. Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy. Clin Pharmacol Ther. 1998;64(3):286-8. [Crossref]  [PubMed] 
  19. Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A. Interaction between grapefruit juice and diazepam in humans. Eur J Drug Metab Pharmacokinet. 1998;23(1):55-9. [Crossref]  [PubMed] 
  20. Kupferschmidt HH, Ha HR, Ziegler WH, Meier PJ, Krähenbühl S. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther. 1995;58(1):20-8. [Crossref]  [PubMed] 
  21. Bedada SK, Boga PK. Influence of diosmin on the metabolism and disposition of carbamazepine in healthy subjects. Xenobiotica. 2017;47(10):879-84. [Crossref]  [PubMed] 
  22. Penzak SR, Robertson SM, Hunt JD, Chairez C, Malati CY, Alfaro RM, et al. Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects. Pharmacotherapy. 2010;30(8):797-805. [Crossref]  [PubMed]  [PMC] 
  23. Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, et al. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther. 2004;75(1):89-100. [Crossref]  [PubMed] 
  24. Zuo XC, Zhang BK, Jia SJ, Liu SK, Zhou LY, Li J, et al. Effects of Ginkgo biloba extracts on diazepam metabolism: a pharmacokinetic study in healthy Chinese male subjects. Eur J Clin Pharmacol. 2010;66(5):503-9. [Crossref]  [PubMed] 
  25. Robertson SM, Davey RT, Voell J, Formentini E, Alfaro RM, Penzak SR. Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Curr Med Res Opin. 2008;24(2):591-9. [Crossref]  [PubMed] 
  26. Uchida S, Yamada H, Li XD, Maruyama S, Ohmori Y, Oki T, et al. Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J Clin Pharmacol. 2006;46(11):1290-8. [Crossref]  [PubMed] 
  27. Gurley BJ, Swain A, Hubbard MA, Hartsfield F, Thaden J, Williams DK, et al. Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. Clin Pharmacol Ther. 2008;83(1):61-9. [Crossref]  [PubMed] 
  28. Mueller SC, Majcher-Peszynska J, Uehleke B, Klammt S, Mundkowski RG, Miekisch W, et al. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose. Eur J Clin Pharmacol. 2006;62(1):29-36. [Crossref]  [PubMed] 
  29. Xie R, Tan LH, Polasek EC, Hong C, Teillol-Foo M, Gordi T, et al. CYP3A and P-glycoprotein activity induction with St. John's Wort in healthy volunteers from 6 ethnic populations. J Clin Pharmacol. 2005;45(3):352-6. [Crossref]  [PubMed] 
  30. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, et al. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging. 2005;22(6):525-39. [Crossref]  [PubMed]  [PMC] 
  31. Johne A, Perloff ES, Bauer S, Schmider J, Mai I, Brockmöller J, et al. Impact of cytochrome P-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteers. Eur J Clin Pharmacol. 2004;60(9):617-22. [Crossref]  [PubMed] 
  32. Wang LS, Zhu B, Abd El-Aty AM, Zhou G, Li Z, Wu J, Chen GL, Liu J, Tang ZR, An W, Li Q, Wang D, Zhou HH. The influence of St John's Wort on CYP2C19 activity with respect to genotype. J Clin Pharmacol. 2004 Jun;44(6):577-81. [Crossref]  [PubMed] 
  33. Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, et al. The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther. 2003;74(6):525-35. [Crossref]  [PubMed] 
  34. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther. 2002;72(3):276-87. [Crossref]  [PubMed] 
  35. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther. 2001;70(4):317-26. [Crossref]  [PubMed] 
  36. Burstein AH, Horton RL, Dunn T, Alfaro RM, Piscitelli SC, Theodore W. Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther. 2000;68(6):605-12. [Crossref]  [PubMed] 
  37. Chen LC, Chou MH, Lin MF, Yang LL. Lack of pharmacokinetic interaction between valproic acid and a traditional Chinese medicine, Paeoniae Radix, in healthy volunteers. J Clin Pharm Ther. 2000;25(6):453-9. [Crossref]  [PubMed] 
  38. Bedada SK, Appani R, Boga PK. Effect of piperine on the metabolism and pharmacokinetics of carbamazepine in healthy volunteers. Drug Res (Stuttg). 2017;67(1):46-51. [Crossref]  [PubMed] 
  39. Pattanaik S, Hota D, Prabhakar S, Kharbanda P, Pandhi P. Effect of piperine on the steady-state pharmacokinetics of phenytoin in patients with epilepsy. Phytother Res. 2006;20(8):683-6. [Crossref]  [PubMed] 
  40. Velpandian T, Jasuja R, Bhardwaj RK, Jaiswal J, Gupta SK. Piperine in food: interference in the pharmacokinetics of phenytoin. Eur J Drug Metab Pharmacokinet. 2001;26(4):241-7. [Crossref]  [PubMed] 
  41. Bano G, Amla V, Raina RK, Zutshi U, Chopra CL. The effect of piperine on pharmacokinetics of phenytoin in healthy volunteers. Planta Med. 1987;53(6):568-9. [Crossref]  [PubMed] 
  42. Etman MA. Effect of a bulk forming laxative on the bioavailability of carbamazepine in man. Drug Dev Ind Pharm. 1995;21(16):1901-6. [Crossref] 
  43. Bedada SK, Nearati P. Effect of resveratrol on the pharmacokinetics of carbamazepine in healthy human volunteers. Phytother Res. 2015;29(5):701-6. [Crossref]  [PubMed] 
  44. Xin HW, Wu XC, Li Q, Yu AR, Xiong L. Effects of Schisandra sphenanthera extract on the pharmacokinetics of midazolam in healthy volunteers. Br J Clin Pharmacol. 2009;67(5):541-6. [PubMed]  [PMC] 
  45. Lilja JJ, Backman JT, Neuvonen PJ. Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam--probes of CYP2C9, CYP1A2, and CYP3A4. Clin Pharmacol Ther. 2007;81(6):833-9. [Crossref]  [PubMed] 
  46. Razavi BM, Hosseinzadeh H. A review of the effects of Citrus paradisi (grapefruit) and its flavonoids, naringin, and naringenin in metabolic syndrome. In: Watson RR, Preedy VR, eds. Bioactive Food as Dietary Interventions for Diabetes 2nd ed. London: Academic Press; 2019. p.515-43. [Crossref] 
  47. Karmakar S, Biswas S, Bera R, Mondal S, Kundu A, Ali MA, et al. Beverage-induced enhanced bioavailability of carbamazepine and its consequent effect on antiepileptic activity and toxicity. J Food Drug Anal. 2015;23(2):327-34. [Crossref]  [PubMed] 
  48. Sahi J, Reyner EL, Bauman JN, Gueneva-Boucheva K, Burleigh JE, Thomas VH. The effect of bergamottin on diazepam plasma levels and P450 enzymes in beagle dogs. Drug Metab Dispos. 2002;30(2):135-40. [Crossref]  [PubMed] 
  49. Girennavar B, Jayaprakasha GK, Patil BS. Potent inhibition of human cytochrome P450 3A4, 2D6, and 2C9 isoenzymes by grapefruit juice and its furocoumarins. J Food Sci. 2007;72(8):C417-21. [Crossref]  [PubMed] 
  50. Aktay G, Hancı İH, Balseven A. İlaç etkileşimleri ve hekim sorumluluğu. Sted. 2003;12(7):261-4. [Link] 
  51. Ho PC, Saville DJ, Wanwimolruk S. Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J Pharm Pharm Sci. 2001;4(3):217-27. [PubMed] 
  52. Seden K, Dickinson L, Khoo S, Back D. Grapefruit-drug interactions. Drugs. 2010;70(18):2373-407. [Crossref]  [PubMed] 
  53. Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H, et al. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos. 2005;33(4):518-23. [Crossref]  [PubMed] 
  54. Nishimuta H, Ohtani H, Tsujimoto M, Ogura K, Hiratsuka A, Sawada Y. Inhibitory effects of various beverages on human recombinant sulfotransferase isoforms SULT1A1 and SULT1A3. Biopharm Drug Dispos. 2007;28(9):491-500. [Crossref]  [PubMed] 
  55. Mochizuki K, Hamano Y, Miyama H, Arakawa K, Kobayashi T, Imamura H. Successful treatment of a case with concurrent ingestion of carbamazepine overdose and grapefruit juice. Acute Med Surg. 2015;3(1):36-38. [Crossref]  [PubMed]  [PMC] 
  56. Demirezer LÖ. FFD Monografları Tedavide Kullanılan Bitkiler. 1. Baskı. Ankara: Akademisyen Kitabevi Dağıtım Bil.Terc. İth. İhr.Tic. A.Ş.; 2011.
  57. European Medicines Agency-Committee on Herbal Medicinal Products [İnternet] EMA © [Erişim tarihi: 3 Mart 2022] Erişim linki: [Link] 
  58. European Scientific Cooperative on Phytotherapy: ESCOP Monographs. The Scientific Foundation for Herbal Medical Products. 2nd ed. Exeter, UK: ESCOP, the European Scientific Cooperative on Phytotherapy; and Stuttgart and New York: Thieme Scientific Publishers; 2003.
  59. Kubota Y, Kobayashi K, Tanaka N, Nakamura K, Kunitomo M, Umegaki K, et al. Pretreatment with Ginkgo biloba extract weakens the hypnosis action of phenobarbital and its plasma concentration in rats. J Pharm Pharmacol. 2004;56(3):401-5. [Crossref]  [PubMed] 
  60. Deng Y, Bi HC, Zhao LZ, Wang XD, Chen J, Ou ZM, et al. Induction of cytochrome P450 3A by the Ginkgo biloba extract and bilobalides in human and rat primary hepatocytes. Drug Metab Lett. 2008;2(1):60-6. [Crossref]  [PubMed] 
  61. Yeung EY, Sueyoshi T, Negishi M, Chang TK. Identification of Ginkgo biloba as a novel activator of pregnane X receptor. Drug Metab Dispos. 2008;36(11):2270-6. [Crossref]  [PubMed]  [PMC] 
  62. Satsu H, Hiura Y, Mochizuki K, Hamada M, Shimizu M. Activation of pregnane X receptor and induction of MDR1 by dietary phytochemicals. J Agric Food Chem. 2008;56(13):5366-73. [Crossref]  [PubMed] 
  63. Gaudineau C, Beckerman R, Welbourn S, Auclair K. Inhibition of human P450 enzymes by multiple constituents of the Ginkgo biloba extract. Biochem Biophys Res Commun. 2004;318(4):1072-8. [Crossref]  [PubMed] 
  64. Kupiec T, Raj V. Fatal seizures due to potential herb-drug interactions with Ginkgo biloba. J Anal Toxicol. 2005;29(7):755-8. [Crossref]  [PubMed] 
  65. Granger AS. Ginkgo biloba precipitating epileptic seizures. Age Ageing. 2001;30(6):523-5. [Crossref]  [PubMed] 
  66. Samuels N, Finkelstein Y, Singer SR, Oberbaum M. Herbal medicine and epilepsy: proconvulsive effects and interactions with antiepileptic drugs. Epilepsia. 2008;49(3):373-80. [Crossref]  [PubMed] 
  67. Chatterjee P, Franklin MR. Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos. 2003;31(11):1391-7. [Crossref]  [PubMed] 
  68. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther. 2005;77(5):415-26. [Crossref]  [PubMed]  [PMC] 
  69. Etheridge AS, Black SR, Patel PR, So J, Mathews JM. An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med. 2007;73(8):731-41. [Crossref]  [PubMed] 
  70. Izzo AA. Interactions between herbs and conventional drugs: overview of the clinical data. Med Princ Pract. 2012;21(5):404-28. [Crossref]  [PubMed] 
  71. Qi JW, Nakamura K, Hosokawa S, Okada Y, Horiuchi R, Yamamoto K. Time-dependent induction of midazolam-1-hydroxylation enzymes in rats treated with St. John's wort. Biol Pharm Bull. 2005;28(8):1467-71. [Crossref]  [PubMed] 
  72. Monograph. Diosmin. Altern Med Rev. 2004;9(3):308-11. [PubMed] 
  73. Cova D, De Angelis L, Giavarini F, Palladini G, Perego R. Pharmacokinetics and metabolism of oral diosmin in healthy volunteers. Int J Clin Pharmacol Ther Toxicol. 1992;30(1):29-33. [PubMed] 
  74. Tsujimoto M, Horie M, Honda H, Takara K, Nishiguchi K. The structure-activity correlation on the inhibitory effects of flavonoids on cytochrome P450 3A activity. Biol Pharm Bull. 2009;32(4):671-6. [Crossref]  [PubMed] 
  75. Gorgani L, Mohammadi M, Najafpour GD, Nikzad M. Piperine-the bioactive compound of black pepper: from isolation to medicinal formulations. Compr Rev Food Sci Food Saf. 2017;16(1):124-40. [Crossref]  [PubMed] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com